Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane and gemcitabine in advanced adenocarcinoma NSCLC
NCT02303977Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Jun 2015
- Primary completion
- Apr 2020
- Modality
- Polymer-based Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of nab-paclitaxel, gemcitabine in Adenocarcinoma Non-Small Cell Lung Cancer (NSCLC-ADC), sponsored by Abramson Cancer Center. Started Jun 2015; status: completed.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
Adenocarcinoma Non-Small Cell Lung Cancer (NSCLC-ADC)
Beyond the preview
Go deeper on NCT02303977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303977.